<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167904</url>
  </required_header>
  <id_info>
    <org_study_id>2018/648</org_study_id>
    <nct_id>NCT04167904</nct_id>
  </id_info>
  <brief_title>Biomarkers in Patients Hospitalized With Suspected Acute Myocardial Infarction</brief_title>
  <acronym>BIOMAC</acronym>
  <official_title>Biomarkers in Patients Hospitalized With Suspected Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The concentration of troponins in plasma is used for diagnosing acute myocardial infarction.
      Different types of heart-specific troponins can be measured and with different analytical
      methods. The primary aim of this study is to evaluate the diagnostic characteristics of a new
      analytical method for measuring troponin I in diagnosing acute myocardial infarction.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acute myocardial infarction according to the 4th universal definition of myocardial infarction</measure>
    <time_frame>Before discharge from hospital, a median of 2 days</time_frame>
    <description>Metric: Yes/No</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days between hospital discharge and death</measure>
    <time_frame>Within 30 days after hospital discharge</time_frame>
    <description>Metric: Days. The secondary outcome measures will be combined into a composite endpoint reflecting the time between hospital admission and the first secondary outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days between hospital discharge and acute myocardial infarction according to the 4th universal definition of myocardial infarction</measure>
    <time_frame>Within 30 days after hospital discharge</time_frame>
    <description>Metric: Days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days between hospital discharge and coronary revascularization</measure>
    <time_frame>Within 30 days after hospital discharge</time_frame>
    <description>Metric: Days</description>
  </secondary_outcome>
  <enrollment type="Anticipated">4000</enrollment>
  <condition>Myocardial Infarction, Acute</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, lithium heparin plasma and EDTA blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to St. Olavs Hospital (Trondheim University Hospital) with suspected
        acute myocardial infarction without ST-elevations on ECG (NSTEMI).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  hospitalized at St. Olavs hospital

          -  blood sampled for troponin analysis due to suspicion of acute myocardial infarction
             without ST-elevations on ECG less than 4 hours after admitted to the hospital

        Exclusion Criteria:

          -  residency outside Norway

          -  does not understand Norwegian
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gustav Mikkelsen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gustav Mikkelsen, MD</last_name>
    <phone>004772573250</phone>
    <email>gustav.mikkelsen@stolav.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gunhild G Hov, PhD</last_name>
    <phone>+47 41265533</phone>
    <email>Gunhild.Garmo.Hov@stolav.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Olavs hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustav Mikkelsen, Phd</last_name>
      <phone>+4793052614</phone>
      <email>gustav.mikkelsen@stolav.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Troponin I</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Sensitivity and Specificity</keyword>
  <keyword>Receiver operation characteristics curve</keyword>
  <keyword>Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

